Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janet Pope

Showing results (91-100 of 167) with videos related to

Pageof 17
Sort By:
RMD Open|June 9, 2021
Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift)Stanley B Cohen, Janet Pope, Boulos Haraoui, et al.
JAMA|May 11, 2016
Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical TrialsDinesh Khanna, Christopher P Denton, Peter A Merkel, et al.
Arthritis Care & Research|July 4, 2020
Systematic Literature Review of Residual Symptoms and an Unmet Need in Patients With Rheumatoid ArthritisKaleb Michaud, Janet Pope, Mart van de Laar, et al.
Autoimmunity Reviews|June 15, 2020
Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohortJanet Roberts, Daniel Ennis, Marie Hudson, et al.
Arthritis Care & Research|November 11, 2017
Early Rheumatoid Arthritis Presentation, Treatment, and Outcomes in Aboriginal Patients in Canada: A Canadian Early Arthritis Cohort Study AnalysisSujay Nagaraj, Cheryl Barnabe, Orit Schieir, et al.
The Journal of Rheumatology|December 4, 2009
The use of micronutrient supplements is not associated with better quality of life and disease activity in Canadian patients with systemic lupus erythematosusElaheh Aghdassi, Stacey Morrison, Carolina Landolt-Marticorena, et al.
Clinical and Experimental Rheumatology|March 25, 2017
Thresholds for the 28-joint disease activity score (DAS28) using C-reactive protein are lower compared to DAS28 using erythrocyte sedimentation rate in early rheumatoid arthritisBindee Kuriya, Orit Schieir, Daming Lin, et al.
The Lancet. Rheumatology|January 17, 2024
Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): a randomised, phase 3b/4, non-inferiority trialStanley B Cohen, Janet Pope, Boulos Haraoui, et al.
Advances in Therapy|September 22, 2022
Post-switch Effectiveness of Etanercept Biosimilar Versus Continued Etanercept in Rheumatoid Arthritis Patients with Stable Disease: A Prospective Multinational Observational StudyJanet Pope, Stephen Hall, Claire Bombardier, et al.
Rheumatology Advances in Practice|May 14, 2023
Impact of the COVID-19 pandemic on patients with rheumatoid arthritis: data from the Ontario Best Practices Research Initiative (OBRI)Matthew Wong-Pack, Elliot Hepworth, Mohammad Movahedi, et al.
Pageof 17

Showing results (91-100 of 167) with videos related to

Sort By:
Pageof 17
RMD Open|June 9, 2021
Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift)Stanley B Cohen, Janet Pope, Boulos Haraoui, et al.
JAMA|May 11, 2016
Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical TrialsDinesh Khanna, Christopher P Denton, Peter A Merkel, et al.
Arthritis Care & Research|July 4, 2020
Systematic Literature Review of Residual Symptoms and an Unmet Need in Patients With Rheumatoid ArthritisKaleb Michaud, Janet Pope, Mart van de Laar, et al.
Autoimmunity Reviews|June 15, 2020
Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohortJanet Roberts, Daniel Ennis, Marie Hudson, et al.
Arthritis Care & Research|November 11, 2017
Early Rheumatoid Arthritis Presentation, Treatment, and Outcomes in Aboriginal Patients in Canada: A Canadian Early Arthritis Cohort Study AnalysisSujay Nagaraj, Cheryl Barnabe, Orit Schieir, et al.
The Journal of Rheumatology|December 4, 2009
The use of micronutrient supplements is not associated with better quality of life and disease activity in Canadian patients with systemic lupus erythematosusElaheh Aghdassi, Stacey Morrison, Carolina Landolt-Marticorena, et al.
Clinical and Experimental Rheumatology|March 25, 2017
Thresholds for the 28-joint disease activity score (DAS28) using C-reactive protein are lower compared to DAS28 using erythrocyte sedimentation rate in early rheumatoid arthritisBindee Kuriya, Orit Schieir, Daming Lin, et al.
The Lancet. Rheumatology|January 17, 2024
Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): a randomised, phase 3b/4, non-inferiority trialStanley B Cohen, Janet Pope, Boulos Haraoui, et al.
Advances in Therapy|September 22, 2022
Post-switch Effectiveness of Etanercept Biosimilar Versus Continued Etanercept in Rheumatoid Arthritis Patients with Stable Disease: A Prospective Multinational Observational StudyJanet Pope, Stephen Hall, Claire Bombardier, et al.
Rheumatology Advances in Practice|May 14, 2023
Impact of the COVID-19 pandemic on patients with rheumatoid arthritis: data from the Ontario Best Practices Research Initiative (OBRI)Matthew Wong-Pack, Elliot Hepworth, Mohammad Movahedi, et al.
Pageof 17